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Introduction
The discovery of new cancer-driver genes and the enforcement 
of molecules targeting them have changed the landscape of 
Non Small Cell Lung Cancer (NSCLC) treatment.
As a matter of fact, the previous scenario of advanced 
NSCLC treatment has been completely revolutionized, 
switching from a “one size fits all” approach to a personalized 
therapy.
Somatic mutations of the Epidermal Growth Factor 
Receptor (EGFR) tyrosine kinase domain positively 
correlated with clinical responsiveness to specific 
inhibitors: gefitinib, erlotinib and afatinib, two reversible 
and one irreversible EGFR inhibitors, have consistently 
demonstrated significant increase of Response Rate (RR) 
and Progression-Free-Survival (PFS) compared to standard 
chemotherapy in EGFR mutated NSCLC patients with 
advanced disease (1-7).
The Anaplastic Lymphoma Kinase (ALK), firstly 
identified from a chromosomal translocation leading 
to the production of merged proteins in Non-Hodgkin 
lymphomas, was then detected as a fusion with the 
echinoderm microtubule-associated protein-like 4 (EML4) 
in 6.7% of NSCLC patients (8,9). Crizotinib (PF02341066, 
Xalkori) targets EML4-ALK thus gaining astonishing 
response rates in a phase I/II trial and more recently in a 
phase III trial (10,11).
Unfortunately, other biomarkers already identified in 
NSCLC are still “undraggable” and one clear example is 
KRAS. KRAS is a member of the RAS family of oncogenesis, 
involved in signal transduction and tumorigenesis and 
its mutations, frequently in codons 12 and 13, have been 
reported in 20-30% NSCLCS (12-15). Some sign of activity 
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came in the last year from a targeted agent (Selumetinib), 
which compared to standard chemotherapy in KRAS mutated 
patients gave interesting results in terms of RR and PFS (16).
Several other molecular markers’ alterations have 
been described in NSCLC such as: phosphatidylinositol 
3-kinases (PI3K) (2%), lipid kinases that regenerate a key 
mediator between growth-factor receptors and intracellular 
downstream signaling pathways; ERBB-2 (2%); B-RAF 
(1-3%), a Ser-Thr kinase that links RAS GTPases to 
downstream proteins of the MAPK family, thus controlling 
cell proliferation; ROS1 (about 1%), oncogene that encodes 
a transmembrane tyrosine kinase receptor; AKT; RET and 
MET (17-21). 
Since the first MET pathway description, several 
inhibitors have been preclinically and clinically tested, both 
alone and in combination with chemotherapy or other 
targeted therapies.
This paper will focus on MET biology, its role in the cell 
function and tumorigenesis, specifically in lung cancer, as 
well as on the molecules that target it.
Met discovery and mechanism of action
Met is a heterodimer receptor tyrosine kinase composed of 
a α-chain and a β-chain, linked by a disulphide bond. 
Met was originally isolated as the product of a human 
oncogene, trp-met, in tumor cells treated with a chemical 
carcinogen. Met gene encodes a 170-kD protein (p170met) 
that has constitutive and ligand-independent tyrosin-
kinase activity. Met has pivotal functions in embryogenesis 
and organogenesis of placenta, liver, kidney, neurons and 
muscles (22-25). 
Moreover, in vivo, Met receptor activation determines 
a phenomenon called “invasive growth”, which includes 
cell proliferation, scattering, survival, motility and 
invasion, epithelial-mesenchymal transition and branched 
morphogenesis (26,27).
The natural ligand for this receptor is the HGF, produced 
by stromal and mesenchymal cells, that acts primarily on 
Met-expressing epithelial cells in an endocrine and/or 
paracrine fashion (24,28). HGF-induced Met tyrosine kinase 
activation is regulated by paracrine ligand delivery, ligand 
activation at the target cell surface and ligand-activated 
receptor internalization and degradation (29). Going more 
into details, when HGF binds to the Met receptor, Met 
major autophosphorylation sites (located within the tyrosine 
kinase domain) are phosphorylated, with subsequent 
intrinsic catalytic activation of multiple signaling cascades 
involved in cell proliferation, survival, angiogenesis, 
morphogenesis, cell scattering, motility, migration and 
invasion. An activated docking site in the kinase domain 
further recruits intracellular adaptor molecules through 
the SH2 domains and other recognition motifs, such as 
GAB1 (a key coordinator of the cellular responses to Met). 
Downstream signaling of the GRB2-mitogen-activated 
protein kinase (MAPK) cascade, PI3K-mTOR pathway, and 
STAT pathway are eventually activated, mediating various 
cellular functions (27,30,31). Finally, in order to activate the 
receptor, proteolytic cleavage of proHGF is necessary (25).
HGF is mainly produced by stromal tissue like liver 
and bone marrow, and is expressed in a multitude of 
mesenchymal-derived cells. Being Met expression detected 
in the epithelium of most tissues, this indicates that 
HGF-Met signal transduction pathway contributes to 
mesenchymal-epithelial interactions (24,32-34). 
Met downregulation occurs through rapid internalization 
of Met itself and subsequent degradation by the lysosome: 
this process is regulated by ligand-dependent ubiquitination 
of Met, a process also modulated by specific tyrosine 
phosphatases and recently identified as proteins decorin and 
LRIG1 (35,36).
Met can be altered through receptor overexpression, 
genomic amplification, mutations or alternative splicing. 
These alterations lead to signaling deregulation that can 
be mediated through ligand (HGF)-independent receptor 
activation or through its ligand (HGF)-dependent activation 
via autocrine (intratumoral HGF), paracrine (mesenchymal 
or microenvironmental HGF), or endocrine (circulatory 
HGF) loop signaling cascades (29).
HGF and Met are highly expressed in various stem 
and progenitors cells, but are only expressed as low levels 
in their mature cells (25). In preclinical animal models, 
whereas the overexpression of Met and/or HGF has been 
shown to stimulate tumorigenesis and metastasis, down-
regulation of Met or HGF expression resulted in increased 
apoptosis and decreased tumor growth and blood vessel 
density (37-40). Moreover, Met interacts synergistically 
with VEGF to promote angiogenesis, cell proliferation and 
invasion (41). This occurs through the transcriptional up-
regulation of the hypoxia inducible factor-1α and amplified 
HGF signaling, that resulted in both induction of invasion 
and increased expression of VEGF (41). 
Met pathway is also one of the key players in the 
development of acquired resistance to VEGF pathway 
inhibitors: the inhibition of Met expression prevented 
hypoxia-induced invasion growth (42,43).
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The increased Met expression described in case of 
response to ionizing radiation through the ATM-NFκB 
signaling pathway, could lead to radioresistance and cancer 
invasion (44).
Met pathway and cross-talks
The cross-talk of Met with various signaling pathways 
is described in literature and that one between Met and 
EGFR/HER family receptors is particularly important in 
lung cancer (45-49). 
Met and EGF family receptors are often described co-
expressed in tumors and transactivation of Met depends 
on elevated expression of EGFR in many human tumors 
(46,50,51). Conversely, HGF stimulation promotes 
transactivation of EGFR in multiple cell lines, including 
NSCLC (49).
Cooperation between Met and EGFR occurs also 
indirectly: when Met activates Src, this lead to EGFR 
phosphorylation and the creation of docking sites for EGFR 
interactors involved in downstream signaling (52). 
Moreover, through receptor cross-talk, Met exerts a 
key role in the development of resistance to EGFR family 
inhibitors. One example is the stimulation of HER-3 
phosphorylation and signaling to Akt (a key signaling 
molecule required for cell survival and proliferation) when 
Met is amplified and overexpressed (53,54). Inhibition of 
Met in EGFR inhibitors resistant cells, either in vitro or 
in vivo, promotes apoptosis, tumor growth reduction and 
significant necrosis (49,53).
Met and EGFR inhibitors  combined together, 
cooperatively abrogate ErbB3 signaling activation (49). An 
alternative mechanism in this context is the Src-induced 
EGFR phosphorylation (52).
Preclinical data also support that Met cross-talks and 
cooperates with other members of the EGF receptor family, 
including HER2, to enhance cell invasion and this lead to 
the possibility to explore therapeutic activity of dual Met 
and HER2 therapies (55,56).
Stimulation with both HGF and EGF enhances 
downstream activation of several signaling pathways 
including Akt, Erk and STAT3 in a way that Met inhibitors 
abolished their baseline phosphorylation (57,58).
The already mentioned interaction between decorin 
and LRIG1 proteins, promotes ligand-independent 
receptor downregulation and degradation of EGFR family 
members. Decorin binds to the EGFR family, inducing 
receptor dimerization, internalization and eventual 
lysosomal degradation, whereas LRIG1 and EGFR 
associated via their extracellular domains, allow enhanced 
EGFR phosphorylation. Thus, Met promotes resistance to 
VEGFR and EGFR inhibitors (59,60).
Cross-talk between Met and KRAS signaling has also 
been described both in preclinical and clinical findings 
(61,62). Met activates RAS directly or via a protein-tyrosine 
phosphatase (63). Similarly, PI3K could be directly activated 
by Met or indirectly by RAS protein (30).
Moreover, Met directly binds to and sequesters the Fas 
receptor. This interaction prevents Fas self-aggregation 
and ligand binding, thus inhibiting Fas activation and 
apoptosis (64). 
Finally, preclinical studies exploring a combination 
of anti-Met therapeutic agents with mTOR inhibitors 
have also demonstrated an increased growth suppression, 
compared to mTOR inhibitors alone (62). 
Met plays also a functional role in signaling pathways 
mediated by other membrane proteins.  Integrin-
dependent signaling could trigger ligand-independent Met 
phosphorylation following cellular adhesion, and Met and 
integrins might have independent yet synergistic roles in 
cell invasion. Plexins, single-pass transmembrane receptors 
for semaphorins, acts cooperatively with Met for cell 
adhesion and migration (45).
MET and NSCLC
Met receptor is overexpressed in both Small Cell Lung 
Cancer (SCLC) and NSCLC, mainly in non-squamous 
histotype (65-67).
Recent  tumor  microarray  expres s ion  ana lys i s 
demonstrated a 72% Met expression in human lung cancer 
tissue and 40% Met receptor over-expression; such values 
are higher than in breast (16%) and ovarian cancer (31%), 
but lower than in renal (70%) and colorectal cancers (CRC; 
78%) (67). Phospho-Met expression is found to be at the 
highest levels in lung cancer (73%), followed by ovarian 
(33%), breast (23%), and renal (18%) cancer (67). 
Met gene amplification can guide the dependency of 
cell survival and proliferation upon the Met signaling, even 
in lung cancer cell lines. Blocking Met causes significant 
growth inhibition, G1-S arrest and apoptosis in cell lines 
harboring Met gene amplification. When Met is not 
amplified, its levels of activation are low and cells are unable 
to grow (68).
Di f ferent  s tud ies  have  reported  pr imary  Met 
amplification to be in the wide range of 2% to 21%, in 
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NSCLC lung adenocarcinomas, particularly in TKI-naïve 
cohorts (69-72).
In lung cancer, Met receptor mutations were mainly 
found clustered in the non-tyrosine kinase domain, in the 
juxtamembrane (JM) domain and in the sema domain (67). 
These mutations are oncogenic activating variants, that 
result in a deletion in the juxtamembrane domain with 
enhanced oncogenic signaling, tumorigenicity, cell motility, 
and migration (27,73). Met kinase domain mutations have 
been found to be somatically selected in the metastatic 
tissues, compared with the primary solid cancers (74).
Literature data are quite discordant on the prognostic 
value of Met over-expression, amplification and mutation.
The overexpression of circulating Met in patients with 
NSCLC has been strongly associated with early tumor 
recurrence and patients with adenocarcinoma and Met 
amplification have also demonstrated a trend for poor 
prognosis (69,75,76). 
Concerning the correlation between Met FISH status 
and clinical characteristics, only Okuda and colleagues 
demonstrated an association with male gender and smoking 
status, showing also a relationship with high Met gene 
copy number (77). In the same trial, both FISH positive 
and gene amplified cases had a worse prognosis, although 
the difference was not statistically significant and among 
the Met FISH-positive NSCLCs, patients with gene 
amplification showed not significantly worse OS compared 
to those with high polysomy.
All FISH-positive cases had squamous histology, 
adenocarcinoma had Met amplification: high Met gene 
copy number tended to have shorter OS and PFS than 
those with low Met gene copy number, being this difference 
statistically significant only in the squamous histotype.
Moreover, at multivariate analysis done on squamous 
histology, increased Met gene copy number and Met 
amplification were confirmed to be independent poor 
prognostic factors.
No significant difference in prognosis was found in 
patients having adenocarcinoma regardless Met FISH status 
in the korean study. In contrast, Beau-Faller and colleagues 
found a tendency toward shorter event-free survival in 
adenocarcinoma patients with increased Met gene copy 
number, whereas Kanteti and colleagues demonstrated that 
the high Met gene copy number in adenocarcinoma was 
associated with a trend of better prognosis (69). However, 
the above mentioned study has some critical methodology 
aspects as it was conducted on a small sample size and 
qPCR was used as test and not FISH, done on DNA 
samples extracted from formalin-fixed paraffin-embedded 
(FFPE) archival tumor tissues (70).
Capuzzo and colleagues found no patient with EGFR 
mutation was Met FISH positive, but increased Met gene 
copy number significantly correlated with EGFR FISH-
positive status (78).
Acquired Met amplification has also been linked to 
approximately 22% of non-T790M mediated secondary 
gefitinib resistance in NSCLC patients, although it can also 
occur concurrently but independently (52,53,78-80).
Using in vitro cell line models, the Met gene amplification 
in gefitinib-resistant cell clones was identified (53). 
Rho and colleagues tried to demonstrate that Met 
activation, rather than gene amplification, is sufficient to 
promote EGFR resistance, but the activation appear to 
be secondary to increase passage numbers rather than to 
EGFR-Tki exposure (81).
More recently, two prospective analyses have investigated 
the mechanism of EGFR-Tki resistance through the tissue 
rebiopsy: high Met gene copy number was found in 11% 
and 5% of the tissue samples, respectively (82,83).
Met inhibitors
Several inhibitors have been tested so far: they can be 
classified according to their mechanism of action in selective 
Met inhibitors, unselective Met inhibitors and antibodies 
targeting Met or HGF (Figure 1, Table 1).
Selective Met inhibitors
Tivantinib
Tivantinib (ARQ 197) is the first non-ATP-competitive 
small molecule that selectively targets the Met RTK, 
locking and stabilizing the kinase in a “closed” and 
“inactive” conformation, causing the disruption of Met 
phosphorylation and the downstream signaling.
Moreover, tivantinib enhances Met degradation through 
the ubiquitin/proteasome pathway in vitro, induces apoptosis 
in Met activated cell-lines and it’s active in multiple human 
cancer xenografts (84,85).
Tivantinib acts synergically with antiangiogenentc drugs 
in preclinical studies on solid tumor cell lines (86).
Studies in vitro and in vivo demonstrated its activity in 
several types of cancer such as breast, colorectal and gastric 
cancer (85,87).
Met cancer expressing cell lines treated with tivantinib 
displayed either a dose-dependent loss of proliferative 
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capacity or caspase-dependent Met apoptosis, which 
positively correlated with either ligand-dependent Met 
activity or constitutively active Met. Tivantinib does not 
exert any activity in cancer cell lines not expressing Met or 
phospho-Met. 
Tivantinib has been investigated in three phase I trials, as 
single agent and in combination.
In the first dose-escalation phase I trial, tivantinib is 
administered as single-agent in patients with advanced solid 
tumors. Initially, an intermittent dosing was planned but, 
due to the bradycardia experienced in the other phase I 
trial using this schedule, the protocol was amended and the 
following 79 patients received a continuous dose (88). 
No MTD was reached in this study and less than 33% 
of patients experienced DLTs at any given dose. Thus, the 
recommended phase II dose was confirmed at 360 mg twice 
a day as per a concomitant phase I study, where this MTD 
was identified (88).
The most commonly reported drug-related adverse 
events of any grade included fatigue, gastrointestinal (GI) 
disorders (nausea, vomiting and diarrhea) and anemia. 
Pharmacokinetic was linear. There was considerable 
Figure 1 Met inhibitors in the clinic
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inter-patient variability, but no relationship between drug-
related adverse events (AEs), dose and extent of tivantinib 
exposure; consequently, this inter-patient variability was not 
considered relevant for its clinical safety. Partial responses 
registered in this trial were equal to 4.8% (89).
In another phase I trial, two formulations of tivantinib 
were tested: the amorphous and the crystall ine A 
formulation. The trial was lead in a single institution, the 
Royal Marsden Hospital (Sutton, United Kingdom) and 
highlighted the following DLTs: one patient had grade 3 
fatigue at 200 mg, one patient presented a grade 3 febrile 
neutropenia, one other a grade 3 mucositis, one a grade 
3 palmar-plantar erythrodysesthesia and one a grade 3 
hypokalemia at 400 mg. The MTDs- recommended phase 
2 doses (RP2Ds) were 300 mg bi-daily for the amorphous 
formulation and 360 mg bi-daily for the crystalline A 
formulation. The main grade 1-2 AEs, all generally self-
limiting, were fatigue (15.7%), nausea (13.7%), vomiting 
(11.8%). Tivantinib is metabolized by CYP2C19: one 
patient with CYP2C19 deficiency experienced grade 4 
febrile neutropenia and grade 3 mucositis as the drug’s AUC 
was 3-fold higher (90).
The crystalline A formulation of tivantinib resulted 
in lower drug exposure at 300 and 360 mg twice daily, 
compared with the amorphous form at 300 mg twice daily 
(likely due to different dissolution characteristics). RECIST 
stable disease ≥4 months was the best response in 14 
patients, together with minor tumor regressions (88).
As the ratio of the poor metabolizers of CYP2C19 in 
Asians is around 20% (while is very low in Caucasians), 
a Japanese phase I trial was designed to evaluate drug’s 
safety profile of tivantinib in this group of patients with 
metastatic solid tumors and the drug was well tolerated, 
but CYP2C19 genotype clearly affected the exposure and 
the RP2Ds differed for “no poor metabolizers” (360 mg bi-
daily) and for “poor metabolizers” (240 mg bi-daily). Most 
Table 1 Ongoing trials on Met inhibitors
Molecule Targets Type Phase Monotherapy or 
combination
Drug associated Patient populations
Tivantinib c-Met TKI I Combination Topotecan SCLC
II Combination Erlotinib EGFR pos NSLC
II Combination Erlotinib KRAS pos
NSCLC
AMG 337 c-Met TKI I Monotherapy - Solid tumors
Cabozantinib c-Met, VEGFR2, 
RET, Kit, AXL, FLT3
TKI II Monotherapy - Solid tumors
II Monotherapy - KIF5B/RET NSCLC
II Combination Erlotinib EGFR neg NSCLC
Foretinib c-Met, VEGFR, 
PDGFRb, Tie-2, 
RON, Kit, FLT3
TKI I-II Combination Erlotinib NSCLC
Golvatinib c-Met, VEGFR TKI I Monotherapy - Solid tumors
MGCD265 c-Met, VEGFR, 
RON, Tie2
TKI I-II Combination Erlotinib/ Docetaxel NSCLC
Onartuzumab c-Met MoAb II rand Combination CBDCA-Pacl Squamous NSCLC
III Combination Erlotinib Met positive NSCLC
II rand Combination Platinum + Pem; 
Platinum + Pacl + Bev
Non-squamous 
NSCLC
Rilotumumab HGF MoAb I-II Combination Erlotinib NSCLC
CBDCA, carboplatin; Pacl, paclitaxel; Pem, pemetrexed; Bev, bevacizumab; rand, randomised; SCLC, small cell lung cancer; 
NSCLC, non-small cell lung cancer; KRAS, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; EGFR, epidermal growth 
factor; KIF5B/RET, kinesin family member 5B/ret proto-oncogene; Met, met proto-oncogene; TKI, tyrosine kinase inhibitor; MoAb, 
monoclonal antibody
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common AEs were similar to those mentioned above (91). A 
phase III trial was conducted in Asia in advanced NSCLC 
patients, comparing erlotinib + tivantinib versus erlotinib + 
placebo at the dose calculated considering the CYP2C19 
polymorphism (92). A press release in August 2012 
announced a suspension in the accrual for this study, due to 
suspected cases of interstitial lung disease (93).
Based on the preclinical data showing a synergistic 
action between EGFR-TKi and Met inhibitors, an open-
label sequential dose escalation phase I trial on tivantinib + 
erlotinib was set up. Thirty-two metastatic cancer patients 
were included: 59% were males, 75% PS 1 and mean age 
was 60 years. The MTD was not established, however, the 
RP2D was 360 mg bi-daily for tivantinib and 150 mg daily 
for erlotinib. Two DLT were experienced at 360 mg (grade 
4 neutropenia, grade 3 thrombocytopenia), none at 240 
or 120 mg. The most common AEs were cutaneous rash, 
fatigue, nausea, abdominal pain, diarrhea, bradycardia and 
anemia, mostly grade 1 and 2. No drug related death, but 
11% grade 3-4 neutropenia and 8% grade 3-4 nausea were 
recorded (94).
This combination of erlotinib (150 mg daily) + tivantinib 
(360 mg bi-daily) every 4 weeks was further studied in 
a phase II, double-blind, randomized open-label study 
in comparison with erlotinib 150 mg daily + placebo, in 
previously treated locally advanced or metastatic NSCLC 
patients. One hundred and sixty-seven patients were 
enrolled and homogeneously distributed between the two 
arms (mainly males, never or former smoker, with stage 
IV disease and adenocarcinoma histology): 10% in the 
combination arm versus 18% in the standard arm presented 
an EGFR mutation, 10% versus 17% a KRAS mutation, 
26% versus 26.5% had 4 or more MET gene copy number. 
The ORR was 10% for erlotinib + tivantinib versus 7% for 
the control arm.
Median investigator’s PFS was 3.8 months for the 
tivantinib + erlotinib arm versus 2.3 months for the erlotinib + 
placebo arm (HR=0.81, P=0.24); the reviewer’s PFS was 
3.6 versus 2 months (HR=0.74, P=0.09). Median OS was 
8.5 for the investigational arm versus 6.9 months for the 
control arm (HR=0.87, P=0.47). Pre-planned exploratory 
survival analysis in non-squamous histology showed a trend 
of benefit from the combination arm in both PFS (HR=0.71) 
and OS (HR=0.72). Even in a small number of patients, 
the subgroup analysis showed an advantage in terms of 
PFS for EGFR wild type (HR=0.70), KRAS mutated 
patients (HR=0.76) and for Met FISH positive patients (>5, 
HR=0.45).
Treatment was well tolerated both in the investigational 
and in the control arm: low grade rash (9.5% versus 7.2%) 
and diarrhea (7.1% versus 7.2%), fatigue (4.8% versus 6%), 
nausea (1.2% versus 4.8%), vomiting (3.6% versus 1.2%), 
dyspnea (7.1% versus 13.3%), anemia (6% versus 7.2%) 
were the most common reported toxicities (95).
On the basis of data coming from this phase II trial, the 
phase III MARQUEE trial was designed in non-squamous 
NSCLC patients with the same schema, having the overall 
survival (OS) as primary end-point. Unfortunately, a press 
release in October 2012, revealed that the primary end 
point in the intent to treat population was not met, but no 
further data are yet available (96,97).
Others selective Met inhibitors 
PF-04217903 is a selective ATP-competitive small inhibitor 
of Met kinase. It inhibits tumor cell proliferation, survival, 
migration/invasion in Met-amplified cell lines in vitro, 
and shows marked antitumor activity in tumor models 
harbouring either Met gene amplification or a HGF/Met 
autocrine loop. PF-04217903 also demonstrates potent 
antiangiogenic properties in vitro and in vivo (98). In 2012 
a phase I trial with PF-04217903 in patients with advanced 
solid tumors was prematurely discontinued, due to strategic 
development decision by Pfizer. No safety concerns were 
reported (99).
AMG 337 is a selective inhibitor of the proto-oncogene 
Met thereby disrupting Met signal transduction pathway. 
A phase I, open-label, sequential dose escalation and 
expansion study with AMG 337 in subjects with advanced 
solid tumors is currently ongoing (100) (Table 1). 
INCB028060 is an oral potent and highly selective Met 
inhibitor, capable of suppressing tumor growth in vivo at 
doses that are extremely well tolerated (101,102). 
Good tolerance was confirmed in a phase I standard 3+3 
dose-escalation study once or twice daily on a continuous 
28-day schedule in patients with advanced solid tumors. 
The MTD was not reached and no grade 3-4 AEs were 
noted, except grade 3 ALT increase in a patient with liver 
metastases and grade 2 ALT levels at baseline. Grade 
1-2 AEs experienced were mild tremor, fatigue, nausea, 
diarrhea, indigestion and headache (103).
Non-selective Met inhibitors
Crizotinib
Crizotinib was synthesized primarily as a Met inhibitor. 
It was engineered based on interactions of a precursor 
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(PHA-665752) with the ATP-binding sites of the Met 
kinase domain thus resulting in displacement of the kinase 
activation loop, that interferes with ATP and substrate 
binding to the Met receptor tyrosine kinase. Crizotinib was 
designed in order to be less lipophilic and to have a small 
hinge binder with the possibility to better interact in the 
kinase pocket (104). 
Crizotinib was proved to be active in NSCLC cell 
lines carrying Met amplification. However, no activity 
was described in Met mutated, EGFR mutated or normal 
cell lines. Moreover, crizotinib markedly inhibited AKT, 
Met and ERK phosphorylation. By doing that, it induced 
apoptosis even though a mediation of BIM up-regulation 
(pro-apoptotic member of the Bcl-2 family) and survivin 
down-regulation (a member of the inhibitor of apoptosis 
protein family) has also been reported. 
Interestingly, in Met or EGFR mutated but also in 
normal cell lines, whit a low Met phosphorylation, the Met 
phosphorylation is completely inhibited, whereas the ERK 
and AKT are not (105). 
During drug development, Ou and colleagues described 
a case of prolonged partial response to crizotinib in a 
NSCLC patient carrying Met amplification (defined as 
Met/CEP7 ratio >5) but no ALK translocation (106).
The first phase I trial was designed as open-label, 
multicenter, to evaluate safety and efficacy of crizotinib: 
this study was emended with an expanded cohort for 
patients with lung cancers carrying ALK rearrangements. 
The recommended crizotinib dose was 250 mg twice daily 
in 28-day cycles. 
In the overall NSCLC population a phase I trial 
investigated crizotinib in association to dose escalating 
erlotinib: 5 DLTs were reported (at 150/100 mg grade 
2 vomiting, grade 2 esophagitis and dysphagia, grade 3 
diarrhea and dehydration; at 200/100 mg, grade 3 dry eye 
and grade 3 esophagitis). Ninety-two percent of the patients 
experienced treatment-related AEs, mainly grade 1 or grade 
2: diarrhea (72%), rash (56%) and fatigue (44%) (107).
Another phase I trials evaluated crizotinib in combination 
with dacomitinib, an irreversible pan-erb inhibitor in 
previously treated advanced NSCLC patients (108). 
Cabozantinib
Cabozantinib (XL184) is a potent Met/VEGFR2/RET/
KIT/AXL/FLT3 inhibitor that targets tumor survival, 
metastasization and angiogenesis.
It selectively inhibits KIT, RET, AXL, TIE2 and FLT3 
(all kinases implicated in tumor pathobiology) through 
strong, reversible, ATP-competitive binding. Moreover, 
cabozantinib inhibits HGF and VEGF-mediated cell 
migration and also Met and VEGFR phosphorylation and 
the tubule formation, with no evidence of cytotoxicity.
This effect described in vitro, turned into in vivo significant 
tumor regression, without any relevant toxicity (109).
Several phase I trials have already been published verifying 
the schedule, the formulation, the dose of the drug, both as 
single-agent and in combination with other molecules.
Kurzrock and col leagues  s tudied s ingle-agent 
cabozantinib both in suspension and capsule formulation, 
at intermittent (5 days on, 9 off) and continuous schedule: 
MTD was defined at 175 mg continuous schedule, being DLT 
mucositis, elevated lipase and altered liver function (110).
The continuous dose was further investigated in a 
Japanese only population: MTD was 60 mg, being grade 3 
hypertension the DLT (111).
Regarding combination regimens, a phase I study 
analyzed the interaction of the combination cabozantinib 
and rosiglitazone, as the latter is a CYP2C8 substrate, but no 
interaction was found between these two compounds (112,113).
Cabozantinib was further studied in several phase II 
trials in different tumor types. Among them, one phase II 
trial investigated treatment with cabozantinib in NSCLC 
patients previously treated with anti-EGFR TKi (50%) 
and anti-VEGF therapies (32%). At week 12 the ORR was 
10% and the overall DCR 40%. No difference in terms of 
PFS (median 4.2 months) was seen in the two populations 
according to the treatment response at 12 weeks. The most 
common grade 3-4 events were diarrhea (7%), palmar-
plantar erythrodyesthesia (8%), fatigue (13%) and asthenia 
(7%) (114).
Likewise tivantinib, also cabozantinib was tested together 
with erlotinib or gefitinib in vivo and in vitro in EGFR 
TKi resistant NSCLC xenograft models harboring Met 
amplification. Gefitinib and cabozantinib were tested on 
gefitinib resistant cell lines either alone and in combination 
and the two molecules together were substantially more 
potent than each drug alone (>50% inhibition). The same 
result was obtained with the combination of erlotinib and 
cabozantinib on erlotinib resistant cell lines (115).
The combination of cabozantinib and erlotinib was 
tested on 54 NSCLC patients in a phase Ib/II study. 
Patients were divided into 5 cohorts in two parallel arms: 
arm A (75 mg cabozantinib + 100 mg erlotinib; 125 mg 
cabozantinib + 100 mg erlotinib; 125 mg cabozantinib + 
50 mg erlotinib) and arm B (75 mg cabozantinib +150 mg 
erlotinib; 50 mg cabozantinib +150 mg erlotinib). Twelve 
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patients experienced at least 1 DLT: diarrhea, increased 
AST levels, palmar-plantar erythrodysesthesia, mucositis, 
hypertension, hypokalemia, elevated lipase and fatigue. The 
most common grade 3-4 adverse events were diarrhea (26%), 
fatigue (15%), dyspnea (12%) and hypoxia (9%) (116).
In advanced NSCLC patients two phase II trials are 
ongoing: the first one randomizes EGFR wild type patients 
to erlotinib, cabozantinib or erlotinib plus cabozantinib as 
second or third line therapy; the second study investigates 
cabozantinib in patients with KIF5B/RET positive NSCLC 
(117,118) (Table 1).
Foretinib
Foretinib (XL-880, EXEL-2880) is an oral multi-kinase 
inhibitor developed to target Met and several other receptor 
tyrosine kinases involved in tumor angiogenesis. It is an 
ATP-competitive inhibitor and binds the ATP pocket of 
both Met and VEGFR-2 tyrosine kinase domains with high 
affinity. 
Both in vitro and in vivo, foretinib inhibits Met and 
VEGF receptor-2 (VEGFR-2) and have high in vitro 
affinity for PDGFRb, Tie-2, RON, Kit, and FLT3 
kinases, preventing tumor growth through a direct effect 
on tumor cell proliferation and inhibition of invasion and 
angiogenesis, mediated by HGF and VEGF receptor (119). 
Two phase I trials have been published: the first 
investigated foretinib administered for 5 consecutive days 
every 14 days in a 3+3 dose escalation study; in the second 
study foretinib was administered once daily for 28 days. 
Both trials were conducted in patients with metastatic or 
unresectable solid tumors. MDT was defined as 3.6 mg/kg 
for 5 consecutive days every 14 days in the first study and as 
80 mg daily in the second; DLTs in the first study included 
grade 3 elevations in aspartate aminotransferase and lipase, 
whereas in the second trial hypertension, dehydration and 
diarrhea were described.
Additional AEs in both studies included hypertension, 
fatigue, diarrhea, vomiting, proteinuria, and hematuria. 
In these studies no responses were observed and most of 
patients achieved a stable disease as best response (120,121). 
A phase I, open-label, randomized, 2-part crossover 
study assessed the safety, pharmacokinetics and relative 
bioavailability of single doses of foretinib free base 
tablet formulation compared to a bisphosphate salt 
capsule formulation: both were well tolerated and their 
pharmacokinetics and relative bioavailability were not 
clinically different (122).
On the basis of preclinical data, showing that combining 
foretinib with erlotinib or lapatinib effectively decrease 
the phosphorylation of Met, HER1, HER2, HER3, AKT, 
and ERK in cell lines, a phase I/II study of erlotinib in 
association or not with foretinib in previously treated 
NSCLC patients has been designed and is currently 
ongoing (123,124) (Table 1).
Golvatinib
Golvatinib (E7050) is a novel small molecule ATP-
competitive inhibitor of Met receptor, that potently and 
selectively inhibits the autophosphorylation of Met and 
VEGF-induced phosphorylation of VEGFR (125).
Golvatinib also circumvents resistance to reversible, 
irreversible, and mutant-selective EGFR-TKIs induced 
by exogenous and/or endogenous HGF in EGFR mutant 
lung cancer cell lines, by blocking the Met/Gab1/PI3K/
Akt pathway in vitro and also prevents the emergence of 
gefitinib-resistant cells, induced by continuous exposure to 
HGF (126).
A phase I study with oral daily golvatinib administered 
continuously once a day in patients with advanced solid 
tumors was performed. Three DLTs were observed: grade 3 
increase in GGT and alkaline phosphatase levels and grade 
3 fatigue, all at 450 mg. The MTD was determined to be 
400 mg every day. Frequently occurring AEs were fatigue 
(68%), diarrhea (65%), nausea (62%), vomiting (53%), 
decreased appetite (47%), ALT increase (38%) and AST 
increase (23%). No grade 4 AEs were observed (127).
Other molecules
MGC D265 is an oral receptor tyrosine kinase inhibitor 
targeting Met, VEGF, RON and Tie2. Preclinical data have 
demonstrated synergism of action with erlotinib and early 
clinical trials are currently ongoing (128) (Table 1). 
ANG707 is another non-selective Met inhibitor under 
investigation in early phase trials (129).
Antibodies
Antibodies against Met
Onartuzumab (MetMab)
MetMAb is a recombinant, fully humanized, monovalent 
monoclonal anti-Met antibody based on the human IgG1k 
framework sequence. It binds in the sema domain of Met 
within the extracellular domain, where it acts to inhibit 
HGF binding and initiation of receptor activation. The 
unique monovalent design of MetMAb eliminates the 
potential for Met activation via antibody-driven receptor 
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dimerization (130).
The activity shown in vitro by MetMAb did not translate 
into a full activity in vivo: only about 65% tumor inhibition was 
demonstrated, indicating that blockade of HGF by MetMAb is 
not sufficient for full tumor inhibition in specific tumors (130).
A phase I trial investigated sequential 3+3 dose-escalation 
of endovenous MetMAb in advanced solid tumors: MetMAb 
was three weekly intravenously administered, both as single 
agent and in combination with bevacizumab 15 mg/kg every 
three weeks, until progression. 
Most frequent MetMAb AEs as single-agent were: 
fatigue (56%), peripheral edema (35%), decreased appetite 
(32%), constipation (29%), nausea (27%), vomiting (24%) 
and hypoalbuminemia (24%); there was no consistent 
relationship between AEs and dose level. 
Grade 3 AEs were peripheral edema (9%), abdominal 
pain, AST increase, fever and hyponatremia. No Grade 4 
toxicity was observed. The combination arm had similar 
toxicities; no grade 3 or 4 toxicity was experienced. MTD 
was not reached. The best response was stable disease (131).
The phase II trial was a global, randomized, double-blind 
trial evaluating the combination of MetMAb + erlotinib 
versus placebo + erlotinib in second/third line NSCLC 
advanced patients. One hundred and twenty-eight NSCLC 
patients were enrolled with a baseline immunohistochemical 
evaluation of Met: 54% of the patients were considered as 
Met positive (high protein expression at IHC). Met positive 
patients treated in the experimental arm had a significantly 
higher PFS (3.0 vs. 1.5 months; HR 0.47; P=0.01) and OS 
(12.6 vs. 4.6 months; HR 0.37; P=0.002) (132).
Based on phase II data, a randomized, phase III, multicenter, 
double-blind, placebo-controlled study evaluating the efficacy 
and safety of onartuzumab in combination with erlotinib 
in patients with Met positive NSCLC who have received 
standard chemotherapy for advanced disease is currently 
recruiting patients (133) (Table 1).
The positive results of the phase I trial on MetMAb in 
combination with bevacizumab have paved the way to the 
ongoing randomized phase II multicentric double-blind 
placebo-controlled study evaluating the efficacy and safety 
of MetMAb in combination with either bevacizumab + 
platinum + paclitaxel or pemetrexed + platinum as first-line 
treatment in patients with stage IIIB and IV non-squamous 
NSCLC (134).
Antibodies against HGF
Ficlatuzumab
Ficlatuzumab (AV-299) is a potent hepatocyte growth 
factor (HGF) inhibitor IgG1 monoclonal antibody, that 
binds to the HGF ligand with high affinity and specificity. 
Ficlatuzumab was studied in two phase I trials and one 
phase II study. In both phase I trials it was associated with 
gefitinib and erlotinib. In the first phase I trial ficlatuzumab 
was biweekly administered intravenously over 30-60 minutes 
both as single-agent and in combination with erlotinib at 
150 mg continuously in advanced solid tumors. There were 
no DLT in the monotherapy arm; consequently no MTD 
was identified.
For the combination arm there was one DLT (grade 
3 mucositis). The RP2D for both monotherapy and 
combination regimen was defined as 20 mg/kg every 
2 weeks. Ficlatuzumab as a single-agent demonstrated a 
stabilisation of disease in 50% of the cases (135).
The second phase Ib trial enrolled only Asiatic patients 
with unresectable NSCLC: ficlatuzumab was administered 
intravenously every 2 weeks at two dose levels (10 and 
20 mg/kg) in combination with gefitinib at 250 mg daily. 
No DLTs were observed in the dose-escalation cohorts; 
20 mg/kg of ficlatuzumab every 2 weeks + gefitinib 250 mg 
daily was selected as RP2D. Among 12 patients in the 
20 mg/kg cohort, 5 partial responses were achieved (136). 
Most frequent treatment-emergent adverse events (AEs) 
were fatigue (27-33%), dermatitis acneiform (53%, 
particularly for the combination regimens), diarrhea (33-
46%) and edema (16-27%) for both single-agent and 
combination therapy (135,136). 
The efficacy of ficlatuzumab together with gefitinib was 
further investigated in a multicenter, open-label, exploratory, 
2-arm randomized phase 2 study in previously untreated 
Asian NSCLC patients with the doses defined in the phase I. 
One-hundred eighty-eight patients were randomized with a 
baseline evaluation of Met by IHC and gene copy number. In 
the low Met group, ORR (41 versus 22%) and median PFS 
(7.3 versus 2.8 m) favored the combination regimen with a 
manageable toxicity profile (137). 
Rilotumumab
Rilotumumab (AMG 102) is a fully human monoclonal 
antibody that selectively targets and neutralizes hepatocyte 
growth factor/scatter factor (HGF/SF). It preferentially 
bound to the β-chain of the human, mature, active form of 
HGF, and had no apparent effect on proteolytic processing 
of the inactive HGF precursor (138).
Two phase I trials have been published so far with AMG 
102 in advanced refractory solid tumors: one as single agent 
and one in combination with bevacizumab or motesanib (139).
In the monotherapy trial, AMG 102 was well tolerated 
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up to the planned maximum dose of 20 mg/kg, MTD was 
not reached and pharmacokinetic was linear. Two patients 
experienced DLTs: one grade 3 hypoxia and grade 3 dyspnea 
(0.5 mg/kg cohort) and one grade 3 upper GI hemorrhage 
(1 mg/kg cohort). Treatment-related AEs were generally 
mild and included fatigue (13%), constipation (8%), 
nausea (8%), vomiting (5%), anorexia (5%), myalgia (5%), 
and hypertension (5%). Seventy percent of the evaluable 
patients had a SD as best response (139).
The phase Ib combination study sequentially enrolled 
patients into four cohorts, but the number of those receiving 
AMG 102 plus motesanib was insufficient to adequately 
assess safety and the accrual was early suspended because 
of reports of cholecystitis in other motesanib studies. No 
dose-limiting toxicities were reported and the combination 
of AMG 102 with bevacizumab seemed to have acceptable 
toxicity. AEs were generally mild and included fatigue 
(75%), nausea (58%), constipation (42%) and peripheral 
edema (42%) (140). 
TAK 701
TAK-701 is a humanized monoclonal antibody that binds 
HGF thus inhibiting its bound to Met receptor. TAK-701 
in combination with gefitinib blocks the phosphorylation 
of Met, EGFR, extracellular signal-regulated kinase, and 
AKT in HGF expressing human NSCLC cell lines with 
an activating EGFR mutation. Combination therapy also 
markedly inhibited the tumor growth in vivo (141). 
Preliminary data of a phase I study in advanced solid 
malignancies with TAK-701 showed that the most common 
AEs were cough, abdominal pain, constipation and fatigue, 
all grade 1-2. There were 3 grade 3 AEs (gastrointestinal 
ileus, pleural effusion, urinary tract infection) and 1 grade 
4 AE (dyspnea). No DLT was found and the MTD has not 
been reached (142).
Conclusions
In patients with advanced NSCLC, a correct definition 
of the histotype is still the first step to design a proper 
therapeutic algorithm, but personalized molecular diagnosis 
is becoming more and more relevant.
Genetically defined subsets of cancers may share 
dependence on a specific signaling pathway: specific 
inhibitors targeting these pathways would be most 
effectively tested in patient populations characterized by 
molecular markers.
Moreover, genetic events that arise and are selected 
during tumor progression may become essential for tumor 
survival, a phenomenon generally described as “oncogene 
addiction”: cancer cells appear to depend on a single 
overactive oncogene to proliferate and survive (143). 
Optimal case selection, diagnostic and pharmacodynamic 
biomarker development, the identification and testing 
of rationally designed anticancer drugs and combination 
strategies are crucial to develop the best treatment for the 
right patient (144).
New generations of molecularly targeted drugs will allow 
more personalized medicine and more efficacious and less 
toxic antitumor therapies in patients with defined molecular 
aberrations, sparing normal cells thus sparing toxicity 
(145,146).
Met can act as an ‘oncogene expedient’ even in absence 
of genetic alterations and might potentiate the effect of 
other oncogenes, promote malignant progression and 
participate in tumor angiogenesis (147). 
Met dysregulation correlates with disease prognosis 
in numerous cancers and represents a possible target 
for personalized treatment. The clinical efficacy of Met 
targeting agents in lung cancer needs further details from 
the ongoing trials as well as more information are necessary 
to establish the most appropriate diagnostic test to identify 
Met expression or amplification. 
Several molecules are currently under investigation and 
two of them already reached phase III trials in advanced 
NSCLC.
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